Lineage Cell Therapeutics
LCTX
105 hedge funds and large institutions have $76.2M invested in Lineage Cell Therapeutics in 2022 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 24 increasing their positions, 23 reducing their positions, and 13 closing their positions.
1,975% more call options, than puts
Call options by funds: $83K | Put options by funds: $4K
31% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 13
4% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 23
4% more capital invested
Capital invested by funds: $73.1M → $76.2M (+$3.03M)
0.15% more ownership
Funds ownership: 38.14% → 38.29% (+0.15%)
0% more funds holding
Funds holding: 105 → 105 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$681K |
| 2 |
Citigroup
New York
|
+$430K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$219K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$196K |
| 5 |
6CM
683 Capital Management
New York
|
+$162K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Raffles Associates
New York
|
-$685K |
| 2 |
E
Ergoteles
New York
|
-$382K |
| 3 |
Two Sigma Advisers
New York
|
-$165K |
| 4 |
Millennium Management
New York
|
-$135K |
| 5 |
DC
Defender Capital
Charlotte,
North Carolina
|
-$114K |
LCTX Hedge Fund Activity: Q4 2022 in Review
105 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q4 2022, worth a combined $76.2M — up 4.1% from $73.1M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new LCTX positions and 13 closed out — a net gain of 4 holders — while 24 added to existing stakes and 23 trimmed.
The largest buyer was Bridgeway Capital Management, adding an estimated $681K. The largest seller was Raffles Associates, cutting an estimated $685K.
- 105 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $76.2M of Lineage Cell Therapeutics stock for Q4 2022, up 4.1% quarter-over-quarter.
- 17 funds opened new Lineage Cell Therapeutics positions in Q4 2022 and 13 closed out, a net change of +4 holders.
- The largest Lineage Cell Therapeutics buyer in Q4 2022 was Bridgeway Capital Management, an estimated $681K added.
- The largest Lineage Cell Therapeutics seller in Q4 2022 was Raffles Associates, an estimated $685K sold.
Based on aggregated 13F filings for Q4 2022.